Back to Search
JAEJOONG KIM, MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1306582457Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Clinical Trials (1)
1
Linked Trials
0
Recruiting
0
With Results
Research & Publications (20)
Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab.
PMID 39978685·J Allergy Clin Immunol·2025
8-other
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
PMID 30097359·Lancet·2018
3-trial
Proportion of CD4CD49bLAG-3Type 1 Regulatory T Cells in the Blood of Psoriasis Patients Inversely Correlates with Psoriasis Area and Severity Index.
PMID 29890167·J Invest Dermatol·2018
8-other
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
PMID 28927890·J Invest Dermatol·2018
3-trial
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
PMID 28423301·N Engl J Med·2017
3-trial
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
PMID 27686018·Annu Rev Med·2017
6-review
The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.
PMID 27185339·J Invest Dermatol·2016
4-observational
Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions-Lessons Learned From Focus Groups.
PMID 27028481·JAMA Dermatol·2016
8-other
Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.
PMID 26763436·J Invest Dermatol·2016
4-observational
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
PMID 25769911·J Allergy Clin Immunol·2015
2-rct
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.
PMID 14707118·J Exp Med·2004
4-observational
Monitoring the intracellular metabolism of nucleoside phosphoramidate pronucleotides by 31P NMR.
PMID 15043168·Nucleosides Nucleotides Nucleic Acids·2004
8-other
Obesity and the risk of early and late mortality after coronary artery bypass graft surgery.
PMID 12947378·Am Heart J·2003
8-other
A nonheme iron(II) complex that models the redox cycle of lipoxygenase.
PMID 11315563·J Biol Inorg Chem·2001
8-other
Three-dimensional porous biodegradable polymeric scaffolds fabricated with biodegradable hydrogel porogens.
PMID 19216632·Tissue Eng Part C Methods·2009
8-other
A copula method for modeling directional dependence of genes.
PMID 18447957·BMC Bioinformatics·2008
8-other
[The incidence rate of hepatitis B virus surface gene variants in Korean children with immunoprophylaxis failure of perinatal infection].
PMID 16380661·Korean J Hepatol·2005
8-other
The tandem BRCT domains of Ect2 are required for both negative and positive regulation of Ect2 in cytokinesis.
PMID 15545273·J Biol Chem·2005
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2450 RIVERSIDE AVE
MINNEAPOLIS, MN 55454 - Phone
- (612) 273-9824
Quick Facts
- NPI
- 1306582457
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile